CGONSeeking AlphaCG Oncology: A Second-Mover Advantage In Bladder-Sparing Therapy
CG Oncology is well-positioned to enter a de-risked NMIBC market with cretostimogene, offering a clean tolerability profile and randomized Phase 3 data. CGON's $1B+ cash position funds operations through 2029, with recent ATM activity signaling strong institutional interest rather than funding desperation. PIVOT-006 trial and BLA completion are imminent catalysts; positive results could unlock significant intermediate-risk NMIBC market potential.
seekingalpha.comRead the article